The DOI matches its Crossref record.
Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and Ribavirin
Abstract
Studies have suggested that African American patients infected with hepatitis C virus (HCV) do not respond as well to treatment with interferon (IFN) as white patients. Here we analyzed the difference in the viral kinetic response between genotype 1 HCV–infected African American patients (n = 19) and white patients (n = 16). Patients were treated with 10 mIU IFN–α2b daily with or without ribavirin for 1 month followed by 3 mIU IFN–α2b 3 times a week with ribavirin. The kinetic parameters (ε, treatment effectiveness at inhibiting virion production; δ, loss rate of virus–producing cells; c, clearance rate of free virions; τ, delay until viral decline starts) were estimated from the viral load decay profiles using a previously described mathematical model. Differences in early kinetic parameters and viral negativity frequencies at weeks 4, 12, and 48 were compared. Ribavirin did not appear to enhance any of the viral kinetic parameters, although this may have been due to the high dose of IFN used. African American patients exhibited significantly (P = .005) lower drug effectiveness (88.6% vs. 98.2%) compared with white patients, accounting for a 0.8 log lower HCV RNA decrease in the first 24 hours of treatment. Significant differences (P = .006) were also noted for δ. There was no correlation between any of the viral kinetic parameters and either age, body mass index (BMI), or genotype 1 subtype. No patient achieved viral negativity at weeks 4, 12, or 48 without an ε greater than 90%. The mean viral decline and viral negativity rates were statistically different between the two races; however, when controlling for treatment effectiveness, these differences were no longer apparent. In conclusion, the failure of IFN response in African American patients infected with genotype 1 HCV is in part due to an impaired ability to inhibit viral production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 992
Muir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032502 · Cited by 541
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
Dixit, N. M., Layden-Almer, J. E., Layden, T. J., & Perelson, A. S. (2004) · Nature · doi:10.1038/nature03153 · Cited by 369
Self-citationRacial/ethnic differences in drug disposition and response: Review of recently approved drugs
Ramamoorthy, A., Pacanowski, M., Bull, J., & Zhang, L. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.61 · Cited by 341
Metadata
- Authors
- Layden-Almer, J. E., Ribeiro, R. M., Wiley, T., Perelson, A. S., & Layden, T. J.
- Venue
- Hepatology
- Published
- 2003-06
- Volume
- 37
- Issue
- 6
- Pages
- 1343-1350
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2014388600
- Cited by
- 184
- References
- 0
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and Ribavirin. https://app.cochat.ai/papers/10.1053/jhep.2003.50217
- The paper
- Layden-Almer, J. E., Ribeiro, R. M., Wiley, T., Perelson, A. S., & Layden, T. J. (2003). Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and Ribavirin. Hepatology. https://doi.org/10.1053/jhep.2003.50217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.